@article{MTMT:35741354,
	title = {The Complex Nomenclature of Allergic Diseases and Hypersensitivity Reactions: an Addendum to the EAACI Position Paper},
	url = {https://m2.mtmt.hu/api/publication/35741354},
	author = {Szegedi, Andrea and Komlósi, Zsolt and Kapitány, Anikó and Csörgő Sándorné Bata, Zsuzsanna and Koncz, Gábor and Bácsi, Attila},
	doi = {10.1111/all.16486},
	journal-iso = {ALLERGY},
	journal = {ALLERGY: EUROPEAN JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY},
	volume = {80},
	unique-id = {35741354},
	issn = {0105-4538},
	year = {2025},
	eissn = {1398-9995},
	pages = {1162-1165},
	orcid-numbers = {Komlósi, Zsolt/0000-0002-4149-1497; Csörgő Sándorné Bata, Zsuzsanna/0000-0002-3732-1743}
}

@article{MTMT:35783046,
	title = {Predictors of response to intravenous immunoglobulin in patients with dermatomyositis: the ProDERM study},
	url = {https://m2.mtmt.hu/api/publication/35783046},
	author = {Charles-Schoeman, Christina and Schessl, Joachim and Csörgő Sándorné Bata, Zsuzsanna and Dimachkie, Mazen M and Griger, Zoltán and Moiseev, Sergey and Oddis, Chester V and Schiopu, Elena and Vencovsky, Jiri and Clodi, Elisabeth and Levine, Todd and Aggarwal, Rohit},
	doi = {10.1093/rheumatology/keaf070},
	journal-iso = {RHEUMATOLOGY},
	journal = {RHEUMATOLOGY (UNITED KINGDOM)},
	volume = {64},
	unique-id = {35783046},
	issn = {1462-0324},
	abstract = {OBJECTIVES: The phase 3 ProDERM study demonstrated intravenous immunoglobulin (IVIg) was safe and effective in patients with dermatomyositis (DM). This analysis assessed clinical and serological predictors of IVIg response in DM patients from ProDERM.; METHODS: ProDERM was a prospective, randomised, placebo-controlled study of DM patients. For Weeks 0-16, patients received 2.0g/kg IVIg (Octagam, 10%) or placebo every 4weeks. Eligible patients entered the open-label extension phase, where all received IVIg to week 40. Univariate and multivariate analyses examined associations between baseline variables and total improvement score (TIS), including myositis disease activity assessment tool (MDAAT; assessing different organ involvement), and myositis-specific and myositis-associated autoantibodies.; RESULTS: Ninety-five patients were enrolled. Univariate analyses found no significant association between TIS at week 16 or 40 and age; sex; ethnicity; disease duration/activity; cutaneous, skeletal, gastrointestinal or muscle disease activity; or previous failed or concomitant medications.Multivariate analysis found patients with higher MDAAT cutaneous scores had a better chance of at least minimal TIS improvement. Higher MDAAT pulmonary scores were associated with a lower, but still considerable, chance of improvement. Patients with TIF1-gamma antibodies had a better TIS response; however, after controlling for cutaneous disease activity, there was no significant association between antibody classification (including anti-TIF1-gamma) and efficacy outcome.; CONCLUSION: IVIg was effective in treating DM patients regardless of demographic features and autoantibody status (for most autoantibodies). Patients with higher cutaneous disease activity and/or anti-TIF1-gamma responded best to IVIg, while pulmonary disease activity predicted a lower, but still effective, IVIg response, warranting further investigation.; CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, NCT02728752. © The Author(s) 2025. Published by Oxford University Press on behalf of the British Society for Rheumatology.},
	keywords = {Intravenous immunoglobulin; dermatomyositis; autoantibody; Autoimmune; Cutaneous; Anti-TIF1-gamma; myositis-associated antibodies},
	year = {2025},
	eissn = {1462-0332},
	pages = {3767-3776},
	orcid-numbers = {Csörgő Sándorné Bata, Zsuzsanna/0000-0002-3732-1743}
}

@CONFERENCE{MTMT:36055964,
	title = {The proteome of keratinocyte cultures from different types of nonlesional psoriatic skin exhibits distinct characteristics},
	url = {https://m2.mtmt.hu/api/publication/36055964},
	author = {Bozó, Renáta and Virág, Nikolett and Flink, Lili Borbála and Hunyadi-Gulyás, Éva and Darula, Zsuzsanna and Gyulai, Rolland Péter and Kemény, Lajos and Csörgő Sándorné Bata, Zsuzsanna},
	booktitle = {10th ÖGDV SCIENCE DAYS},
	unique-id = {36055964},
	year = {2025},
	pages = {23-23},
	orcid-numbers = {Bozó, Renáta/0000-0003-4242-2474; Gyulai, Rolland Péter/0000-0002-3286-8846; Csörgő Sándorné Bata, Zsuzsanna/0000-0002-3732-1743}
}

@article{MTMT:36118660,
	title = {Safety profile of efgartigimod from global clinical trials across multiple immunoglobulin G-mediated autoimmune diseases},
	url = {https://m2.mtmt.hu/api/publication/36118660},
	author = {Gwathmey, Kelly G and Broome, Catherine M and Goebeler, Matthias and Murai, Hiroyuki and Csörgő Sándorné Bata, Zsuzsanna and Newland, Adrian C and Allen, Jeffrey A and Miyakawa, Yoshitaka and Ulrichts, Peter and Truyen, Luc and Podhorna, Jana and Kerstens, Rene and Steeland, Sophie and Beauchamp, Jon and Guptill, Jeffrey T and Howard, James F Jr},
	doi = {10.1080/1744666X.2025.2497840},
	journal-iso = {EXPERT REV CLIN IMMUNOL},
	journal = {EXPERT REVIEW OF CLINICAL IMMUNOLOGY},
	volume = {21},
	unique-id = {36118660},
	issn = {1744-666X},
	abstract = {BACKGROUND: Efgartigimod is approved in multiple regions for the treatment of gMG, ITP, and CIDP, and is being evaluated in multiple IgG-mediated autoimmune diseases. Here, we report the long-term safety profiles of efgartigimod IV and PH20 SC across different dosing regimens and diseases where efgartigimod has received regulatory approval.; RESEARCH DESIGN AND METHODS: Efgartigimod safety was assessed across dosing regimens and administration routes in Phase 2, placebo-controlled Phase 3, and OLE studies in participants with gMG, ITP, and CIDP. Analyses were performed on all participants who received≥1 dose or partial dose of efgartigimod or placebo. Data from efgartigimod-treated participants were pooled per disease. Event rates were calculated as events per PYFU.; RESULTS: Pooled data included 715 participants representing>850 PYFU. In efgartigimod-treated participants, most TEAEs were mild-to-moderate in severity, with consistently low event rates for TEAE-related treatment discontinuation (range: 0.05-0.47). Severe and serious infection rates were comparable between placebo- and efgartigimod-treated participants. Rates of TEAEs, severe and serious infections, and treatment discontinuation did not increase with prolonged efgartigimod exposure. Efgartigimod did not reduce albumin or increase LDL cholesterol levels.; CONCLUSIONS: Across clinical trials in IgG-mediated autoimmune diseases, efgartigimod was well tolerated with similar safety profiles regardless of dosing regimen.},
	keywords = {SAFETY; CIDP; FcRn; ITP; Subcutaneous; intravenous; efgartigimod},
	year = {2025},
	eissn = {1744-8409},
	pages = {627-638},
	orcid-numbers = {Csörgő Sándorné Bata, Zsuzsanna/0000-0002-3732-1743}
}

@article{MTMT:36204130,
	title = {Beneficial Therapeutic Effect of Endothelin‐Receptor Antagonist in Generalized Morphea: A Report of Two Cases},
	url = {https://m2.mtmt.hu/api/publication/36204130},
	author = {Szadai, Leticia and Belső, Nóra and Ladóczky-Hulló, Daniella and Varga, Erika and Korom, Irma and Csörgő Sándorné Bata, Zsuzsanna},
	doi = {10.1111/ijd.17900},
	journal-iso = {INT J DERMATOL},
	journal = {INTERNATIONAL JOURNAL OF DERMATOLOGY},
	volume = {64},
	unique-id = {36204130},
	issn = {0011-9059},
	year = {2025},
	eissn = {1365-4632},
	pages = {2335-2337},
	orcid-numbers = {Szadai, Leticia/0000-0002-3605-839X; Csörgő Sándorné Bata, Zsuzsanna/0000-0002-3732-1743}
}

@article{MTMT:36245474,
	title = {Efficacy of Intravenous Immunoglobulin for Systemic Manifestations of Dermatomyositis Beyond Muscular and Cutaneous: Sub-analysis of the ProDERM Study},
	url = {https://m2.mtmt.hu/api/publication/36245474},
	author = {Aggarwal, Rohit and Schessl, Joachim and Csörgő Sándorné Bata, Zsuzsanna and Dimachkie, Mazen M. and Griger, Zoltán and Moiseev, Sergey and Oddis, Chester V. and Schiopu, Elena and Vencovsky, Jiri and Clodi, Elisabeth and Levine, Todd and Charles-Schoeman, Christina},
	doi = {10.1007/s40744-025-00775-5},
	journal-iso = {RHEUMATOL THER},
	journal = {RHEUMATOLOGY AND THERAPY},
	volume = {12},
	unique-id = {36245474},
	issn = {2198-6576},
	abstract = {Introduction: Muscle and skin involvement are well defined in dermatomyositis but other symptoms contribute significantly to the disease burden and their treatment is not well characterized. This post hoc analysis of ProDERM assessed the effect of intravenous immunoglobulin (IVIg) treatment on other manifestations of dermatomyositis beyond muscular and cutaneous involvement. Methods: ProDERM was a randomized, placebo-controlled study. For weeks 0-16, patients with dermatomyositis received 2.0 g/kg IVIg (Octagam, 10%) or placebo every 4 weeks. Eligible patients entered the open-label extension, where all received IVIg to week 40. Pulmonary, skeletal, constitutional, gastrointestinal, and cardiovascular disease activity was assessed using the myositis disease activity assessment tool, comprising a visual analog scale (VAS; 0-10 cm) and myositis intention-to-treat activity index. Results: Of 95 patients enrolled, 47 received IVIg and 48 received placebo to week 16. At baseline, 37.9% of patients experienced pulmonary, 64.2% experienced skeletal, 76.8% experienced constitutional, 33.7% experienced gastrointestinal, and 15.8% experienced cardiovascular involvement (VAS > 0.5). Among these patients, for those on IVIg, the following mean VAS scores decreased from baseline to week 16: pulmonary (37.7%; P = 0.001), skeletal (52.6%; P < 0.001), constitutional (44.4%; P < 0.001), and gastrointestinal (49.2%; P = 0.005). No corresponding improvement was seen with placebo except for constitutional VAS. With IVIg, the proportions of patients with arthritis (36.2 to 17.8%; P = 0.01), arthralgia (68.1 to 0.0%; P < 0.001), and fatigue (68.1 to 3.3%; P = 0.008) decreased from baseline to week 16. In the combined cohort, the proportions of patients with dysphonia (20.0 to 8.1%; P = 0.04), arthralgia (66.3 to 39.8%; P < 0.001), weight loss (10.5 to 3.4%; P = 0.04), fatigue (75.8 to 50.0%; P < 0.001), and dysphagia (40.0 to 18.4%; P < 0.001) decreased from baseline to week 40. Conclusion: IVIg was effective in treating pulmonary, skeletal, constitutional, and gastrointestinal manifestations of dermatomyositis. We advocate exploring IVIg as treatment for dermatomyositis, beyond muscle and skin manifestations.},
	keywords = {ARTHRITIS; gastrointestinal; dermatomyositis; Immunoglobulins; arthralgia; PULMONARY; INFLAMMATORY MYOPATHIES; intravenous; constitutional; octagam},
	year = {2025},
	eissn = {2198-6584},
	pages = {855-871},
	orcid-numbers = {Csörgő Sándorné Bata, Zsuzsanna/0000-0002-3732-1743}
}

@article{MTMT:36858088,
	title = {Psoriatic fibroblasts exhibit a distinct transcriptomic profile},
	url = {https://m2.mtmt.hu/api/publication/36858088},
	author = {Flink, Lili Borbála and Ghaffarinia, Ameneh and Bozó, Renáta and Szűcs, Diána and Póliska, Szilárd and Balogh, Fanni and Degovics, Döníz and Veréb, Zoltán and Gyulai, Rolland Péter and Kemény, Lajos and Csörgő Sándorné Bata, Zsuzsanna},
	journal-iso = {IMMUNOLÓGIAI SZEMLE},
	journal = {IMMUNOLÓGIAI SZEMLE},
	volume = {17},
	unique-id = {36858088},
	issn = {2061-0203},
	year = {2025},
	pages = {11-11},
	orcid-numbers = {Bozó, Renáta/0000-0003-4242-2474; Veréb, Zoltán/0000-0002-9518-2155; Gyulai, Rolland Péter/0000-0002-3286-8846; Csörgő Sándorné Bata, Zsuzsanna/0000-0002-3732-1743}
}

@article{MTMT:36858165,
	title = {Proteomic analysis reveals immune-related alterations in keratinocytes from non-lesional and resolved psoriatc skin},
	url = {https://m2.mtmt.hu/api/publication/36858165},
	author = {Bozó, Renáta and Virág, Nikolett and Flink, Lili Borbála and Hunyadi-Gulyás, Éva and Darula, Zsuzsanna and Ayaydin, Ferhan and Farkas, Attila and Gyulai, Rolland Péter and Kemény, Lajos and Csörgő Sándorné Bata, Zsuzsanna},
	journal-iso = {IMMUNOLÓGIAI SZEMLE},
	journal = {IMMUNOLÓGIAI SZEMLE},
	volume = {17},
	unique-id = {36858165},
	issn = {2061-0203},
	year = {2025},
	pages = {24-24},
	orcid-numbers = {Bozó, Renáta/0000-0003-4242-2474; Gyulai, Rolland Péter/0000-0002-3286-8846; Csörgő Sándorné Bata, Zsuzsanna/0000-0002-3732-1743}
}

@article{MTMT:36858531,
	title = {Inflammatory memory of psoriatic resolved keratinocytes},
	url = {https://m2.mtmt.hu/api/publication/36858531},
	author = {Tassi, Nelli and Ghaffarinia, Ameneh and Nagy, Géza Róbert and Gyulai, Rolland Péter and Csörgő Sándorné Bata, Zsuzsanna and Kemény, Lajos and Bozó, Renáta},
	journal-iso = {IMMUNOLÓGIAI SZEMLE},
	journal = {IMMUNOLÓGIAI SZEMLE},
	volume = {17},
	unique-id = {36858531},
	issn = {2061-0203},
	year = {2025},
	pages = {45-45},
	orcid-numbers = {Nagy, Géza Róbert/0000-0002-3876-0422; Gyulai, Rolland Péter/0000-0002-3286-8846; Csörgő Sándorné Bata, Zsuzsanna/0000-0002-3732-1743; Bozó, Renáta/0000-0003-4242-2474}
}

@article{MTMT:36859195,
	title = {Inflammatory memory of psoriatic resolved keratinocytes},
	url = {https://m2.mtmt.hu/api/publication/36859195},
	author = {Tassi, Nelli and Ghaffarinia, Ameneh and Nagy, Géza Róbert and Gyulai, Rolland Péter and Csörgő Sándorné Bata, Zsuzsanna and Kemény, Lajos and Bozó, Renáta},
	journal-iso = {BVSZ},
	journal = {BŐRGYÓGYÁSZATI ÉS VENEROLÓGIAI SZEMLE},
	volume = {101},
	unique-id = {36859195},
	issn = {0006-7768},
	year = {2025},
	eissn = {2064-261X},
	pages = {291-292},
	orcid-numbers = {Nagy, Géza Róbert/0000-0002-3876-0422; Gyulai, Rolland Péter/0000-0002-3286-8846; Csörgő Sándorné Bata, Zsuzsanna/0000-0002-3732-1743; Bozó, Renáta/0000-0003-4242-2474}
}